Skip to main content

Table 2 Laboratory findings, CSF analysis, and NCS/EMG results

From: Clinical features with anti fibroblast growth factor receptor 3 (FGFR3) antibody-related polyneuropathy: a retrospective study

Laboratory findings FGFR3 antibody (≥3000) 14,285.71 (IQR 5000–16,750)
CSF analysis (n = 6) WBC count 0.67 (IQR 0–1)
Protein 40.3 (IQR 38.5–41.5)
Glucose 60 (IQR 58.5–61.5)
NCS/EMG findings Sensory axonal neuropathy 4 (28.6%)
Sensorimotor axonal neuropathy 7 (50%)
Normal result 3 (21.4%)
Type of neuropathy (using results of NCS/EMG and skin biopsy) Non-length-dependent 6 (42.9%)
Length-dependent 8 (57.1%)
  1. Data are reported as n (%) and mean (interquartile range). CSF cerebrospinal fluid, EMG electromyography, FGFR3 fibroblast growth factor receptor 3, NCS nerve conduction studies, WBC white blood cell